AstraZeneca Plc declares results

 

  • Full year 2019 product sales growth came in at 12% to $23,565 million
  • Sales of new medicine came in at $9,906 million
  • Sales growth in Oncology was 44% while that for respiratory diseases was 10%
  • Sales growth in emerging markets was at 18%
  • On 14th February 2020, at the time of writing, GMT 09:52 AM, AZN shares were trading at GBX 7,594, down by 32 points or 0.42% against the previous day closing price